KeifeRx, LLC, is an emerging clinical-stage biopharmaceutical company developing a pipeline of optimized, lower dose, orally delivered tyrosine kinase inhibitors (TKIs) for the treatment of multiple, high-need neurodegenerative diseases. KeifeRx’s optimized TKIs are designed to penetrate the brain, induce autophagy, and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Lewy Body Dementia, through the bulk disposal of disease-causing toxic proteins. This approach offers the potential to significantly improve upon current neurodegenerative disease treatments, which are only palliative and offer minimal benefits due to their inability to adequately eliminate the toxic proteins that are the root of these deadly diseases.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):